So, we are now doing a quick test in Mexico with their "NIH" under the direction of Gustavo Reyes-Terán, named in today's proactive.
Then question is, why is he interested on Leronlimab?? Why does he want to go ahead and try us ?? Well, perhaps the answer is below:
He wrote a book on Influenza as well (see the connection??) and is
the founder of the Infectious Diseases Service for Immunocompromised Patients of the Mexican health system, made in 2001 and in 2004 of the Center for Research on Infectious Diseases (CIENI) at the National Institute of Respiratory Diseases (INER), called the Department of Research on Infectious Diseases.
This department serves as one of the eleven Regional Reference Laboratories accredited by the World Health Organization (WHO) for the investigation of diseases such as HIV and emerging situations such as the 2009-2010 influenza A (H1N1) pandemic in the country, carrying out the complete genomic characterization of the virus. He contributed to the investigation of viruses such as H7N3 influenza type A7 and the Zika virus in Mexico.
In October 2019 he was named coordinator of the "NIH" Mexican (comisionado coordinador de la Comisión Coordinadora de Institutos Nacionales y Hospitales de Alta Especialidad)
In a word, this guy knows what he is dealing with, knows about HIV, knows about influenza and respiratory conditions (hell, wrote a book about it), and knows about virus characterizations.
In summary: he knows about Leronlimab
I hope he does not have the "baggage" that Fauci seems to carry with him (prefer not to elaborate so we don't go into any rabbit holes).
One thing is for sure, if there is somebody that can really appreciate the science of Leronlimab and what we can bring to the table is him.
We are lucky he decided to give us an opportunity in Mexico with their "NIH" (more appropriately called C.C.I.N.S.H.A.E. in Mexico)
Then question is, why is he interested on Leronlimab?? Why does he want to go ahead and try us ?? Well, perhaps the answer is below:
Quote:Gustavo Reyes-Terán (GRT) was the head of the Department of Research in Infectious Diseases, the Director of the Center for AIDS Research and the Coordinator of the HIV/AIDS Clinic at the INER. He is Professor of the Courses of Master and Ph Degrees in Medical and Biomedical Sciences at the National University of Mexico. GRT spent 2 years in San Francisco, completing a Fogarty postdoctoral fellowship in Pathogenesis of HIV Disease at the Cancer Research Institute of the University of California San Francisco (UCSF).
As the Coordinator of the AIDS Clinic of the INER since 2000, GRT has been actively involved in AIDS care and research, participating as principal investigator in phase II-III clinical trials with anti-HIV/AIDS and opportunistic infections therapies, and is currently interested in research on HAART prescription environment in Mexico (including adherence and supply issues).
GRT is an active investigator in both clinical and basic virology, and has been able to raise considerable funds and institutional support to build a new HIV/AIDS research facility within his institution. It now hosts one of the most comprehensive research teams in Mexico and state-of-the-art research labs. Under GRT's direction, HIV/AIDS research, both basic and clinical, is very active at the INER, covering therapeutic, molecular virology, immunogenetic/immunologic, nutritional and behavioral studies, including international collaborations on AIDS pathogenesis research.
He wrote a book on Influenza as well (see the connection??) and is
the founder of the Infectious Diseases Service for Immunocompromised Patients of the Mexican health system, made in 2001 and in 2004 of the Center for Research on Infectious Diseases (CIENI) at the National Institute of Respiratory Diseases (INER), called the Department of Research on Infectious Diseases.
This department serves as one of the eleven Regional Reference Laboratories accredited by the World Health Organization (WHO) for the investigation of diseases such as HIV and emerging situations such as the 2009-2010 influenza A (H1N1) pandemic in the country, carrying out the complete genomic characterization of the virus. He contributed to the investigation of viruses such as H7N3 influenza type A7 and the Zika virus in Mexico.
In October 2019 he was named coordinator of the "NIH" Mexican (comisionado coordinador de la Comisión Coordinadora de Institutos Nacionales y Hospitales de Alta Especialidad)
In a word, this guy knows what he is dealing with, knows about HIV, knows about influenza and respiratory conditions (hell, wrote a book about it), and knows about virus characterizations.
In summary: he knows about Leronlimab
I hope he does not have the "baggage" that Fauci seems to carry with him (prefer not to elaborate so we don't go into any rabbit holes).
One thing is for sure, if there is somebody that can really appreciate the science of Leronlimab and what we can bring to the table is him.
We are lucky he decided to give us an opportunity in Mexico with their "NIH" (more appropriately called C.C.I.N.S.H.A.E. in Mexico)
36
